Table II.
Drug‐Induced Change in Hemodynamic and Wave Reflection Profiles From Baseline in Patients Treated With Atenolol or Controlled‐Release Carvedilol at Week 2 and 4
| Week 2 | Week 4 | |||||
|---|---|---|---|---|---|---|
| Atenolol 50 mg (n=18) | Carvedilol 40 mg (n=22) | P Value Between Treatment | Atenolol 100 mg (n=17) | Carvedilol 80 mg (n=22) | P Value Between Treatment | |
| Brachial systolic blood pressure, mm Hg | −15.7±13.0 | −14.1±12 | .67 | −19.5±17.6 | −17.6±11.3 | .68 |
| Brachial diastolic blood pressure, mm Hg | −15.2±10.2 | −8.1±9.1 | .02 | −15.1±10.4 | −13.1±7.9 | .51 |
| Brachial pulse pressure, mm Hg | −0.5±7.2 | −6±9.0 | .04 | −4.4±11.3 | −4.5±10.8 | .99 |
| Central systolic blood pressure, mm Hg | −13.1±14.3 | −12.4±11.2 | .87 | −16.0±18.7 | −16.1±10.4 | .98 |
| Central diastolic blood pressure, mm Hg | −15.5±10.2 | −8.1±9.3 | .02 | −15.4±10.1 | −13.2±8.1 | .46 |
| Central pulse pressure, mm Hg | 2.4±6.4 | −4.2±7.1 | .004 | −0.7±11.7 | −2.9±9.8 | .51 |
| Heart rate, bpm | −11.7±7.8 | −8.6 ±7.8 | .21 | −12.6 ±7.1 | −10.4 ±10.0 | .45 |
| Pulse pressure amplification, mm Hg | −0.09±0.11 | −0.02±0.09 | .05 | −0.1±0.11 | −0.02±0.11 | .02 |
| Central augmentation pressure, mm Hg | 2.1±4.0 | −1.5±3.1 | .0035 | 1.1±6.0 | −1.1±5.3 | .23 |
| Central augmentation pressure75, mm Hg | −0.7±3.8 | −3.0±2.8 | .04 | −1.2 ±4.3 | −3.1±4.1 | .18 |
| Central augmentation index, % | 4.4±6.9 | 0.0±5.9 | .03 | 4.5±7.7 | −0.7±7.4 | .04 |
| Central augmentation index75, % | −1.3±6.7 | −4.1±5.6 | .15 | −1.6±6.4 | −5.4±6.1 | .06 |
Abbreviations: bpm, beats per minute; central augmentation index75, central augmentation index adjusted at a heart rate of 75 bpm; central augmentation pressure75, central augmentation pressure adjusted at a heart rate of 75 bpm. Values are expressed as mean±standard error of the mean.